GENETIC ANALYSIS NK -60 Cash Flow Conversion Efficiency
GENETIC ANALYSIS NK -60 cash flow conversion efficiency. Based on the latest financial reports, GENETIC ANALYSIS NK -60 (8V8) has a cash flow conversion efficiency ratio of -0.218x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-4.52 Million ≈ $-5.28 Million USD) by net assets (€20.71 Million ≈ $24.22 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of GENETIC ANALYSIS NK -60 (2021–2025)
Cash flow conversion efficiency of GENETIC ANALYSIS NK -60 from 2021 to 2025. This chart illustrates how GENETIC ANALYSIS NK -60's cash flow conversion efficiency has evolved over time, based on yearly financial data. View GENETIC ANALYSIS NK -60 (8V8) share price today for real-time trading data and today's change.
GENETIC ANALYSIS NK -60 Cash Flow Conversion Ratio Explained
GENETIC ANALYSIS NK -60 cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
GENETIC ANALYSIS NK -60 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GENETIC ANALYSIS NK -60 ranked by their cash flow conversion efficiency. Also see 8V8 company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vast Renewables Limited Ordinary Shares
NASDAQ:VSTE
|
0.148x |
|
Tristel
LSE:TSTL
|
0.161x |
|
Helios Energy Ltd
AU:HE8
|
-0.020x |
|
Afentra PLC
LSE:AET
|
0.330x |
|
Himalaya Energi Perkasa Tbk PT
JK:HADE
|
-0.012x |
|
Redhill Biopharma Ltd
NASDAQ:RDHL
|
-0.588x |
|
Discovery Alaska Ltd
AU:DAF
|
-0.122x |
|
Silver Castle Holdings Ltd
TA:SLCL
|
0.557x |
Annual Cash Flow Conversion Efficiency for GENETIC ANALYSIS NK -60 (2021–2025)
The table below shows the annual cash flow conversion efficiency of GENETIC ANALYSIS NK -60 from 2021 to 2025. Review cash generation quality of GENETIC ANALYSIS NK -60 to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €27.08 Million ≈ $31.66 Million |
€2.40 Million ≈ $2.81 Million |
0.089x | +117.16% |
| 2024-12-31 | €22.49 Million ≈ $26.30 Million |
€-11.62 Million ≈ $-13.59 Million |
-0.517x | +4.04% |
| 2023-12-31 | €32.00 Million ≈ $37.41 Million |
€-17.23 Million ≈ $-20.15 Million |
-0.539x | -22.17% |
| 2022-12-31 | €44.14 Million ≈ $51.60 Million |
€-19.46 Million ≈ $-22.75 Million |
-0.441x | -15.07% |
| 2021-12-31 | €72.09 Million ≈ $84.28 Million |
€-27.62 Million ≈ $-32.29 Million |
-0.383x | -- |
About GENETIC ANALYSIS NK -60
Genetic Analysis AS, a science-based diagnostic company, engages in the research, development, manufacturing, and sale of diagnostic test solutions for human microbiome in the United States, Europe, and internationally. The company offers GA-map MHI Gut Health Test, a microbiome-based diagnostic test for antibiotic-induced microbiome imbalances; GA-map Dysbiosis Test, a diagnostic microbiome test… Read more